Venter, W. F., Kaiser, B., Pillay, Y., Conradie, F., Gomez, G. B., Clayden, P., Matsolo, M., Amole, C., Rutter, L., Abdullah, F., Abrams, E. J., Casas, C. P., Barnhart, M., Pillay, A., Pozniak, A., Hill, A., Fairlie, L., Boffito, M., Moorhouse, M., ... Loots, G. (2016). Cutting the cost of South African antiretroviral therapy using newer, safer drugs. South African Medical Journal, 107(1), 28-30. https://doi.org/10.7196/SAMJ.2016.v107.i1.12058
Cutting the cost of South African antiretroviral therapy using newer, safer drugs. / Venter, W. F.; Kaiser, B.; Pillay, Y. et al.
En:
South African Medical Journal, Vol. 107, N.º 1, 21.12.2016, p. 28-30.
Producción científica › revisión exhaustiva
Venter, WF, Kaiser, B, Pillay, Y, Conradie, F, Gomez, GB, Clayden, P, Matsolo, M, Amole, C, Rutter, L, Abdullah, F, Abrams, EJ, Casas, CP, Barnhart, M, Pillay, A, Pozniak, A, Hill, A, Fairlie, L, Boffito, M, Moorhouse, M, Chersich, M, Serenata, C, Quevedo, J & Loots, G 2016, 'Cutting the cost of South African antiretroviral therapy using newer, safer drugs', South African Medical Journal, vol. 107, n.º 1, pp. 28-30. https://doi.org/10.7196/SAMJ.2016.v107.i1.12058
Venter WF, Kaiser B, Pillay Y, Conradie F, Gomez GB, Clayden P et al. Cutting the cost of South African antiretroviral therapy using newer, safer drugs. South African Medical Journal. 2016 dic. 21;107(1):28-30. doi: 10.7196/SAMJ.2016.v107.i1.12058
Venter, W. F. ; Kaiser, B. ; Pillay, Y. et al. / Cutting the cost of South African antiretroviral therapy using newer, safer drugs. En: South African Medical Journal. 2016 ; Vol. 107, N.º 1. pp. 28-30.
@article{968d08c24a88479aaa403309a9abc3fb,
title = "Cutting the cost of South African antiretroviral therapy using newer, safer drugs",
abstract = "Antiretrovirals are a significant cost driver for HIV programmes. Current first-line regimens have performed well in real-life programmes, but have a low barrier to virological resistance and still carry toxicity that limits adherence. New drug developments may mean that we have access to safer, more robust and cheaper regimens, but only if the appropriate clinical trials are conducted. We briefly discuss these trials, and demonstrate the large cost savings to the South African HIV programme if these are successful.",
author = "Venter, {W. F.} and B. Kaiser and Y. Pillay and F. Conradie and Gomez, {G. B.} and P. Clayden and M. Matsolo and C. Amole and L. Rutter and F. Abdullah and Abrams, {E. J.} and Casas, {C. P.} and M. Barnhart and A. Pillay and A. Pozniak and A. Hill and L. Fairlie and M. Boffito and M. Moorhouse and M. Chersich and C. Serenata and J. Quevedo and G. Loots",
year = "2016",
month = dec,
day = "21",
doi = "10.7196/SAMJ.2016.v107.i1.12058",
language = "English",
volume = "107",
pages = "28--30",
journal = "South African Medical Journal",
issn = "0256-9574",
publisher = "South African Medical Association",
number = "1",
}
TY - JOUR
T1 - Cutting the cost of South African antiretroviral therapy using newer, safer drugs
AU - Venter, W. F.
AU - Kaiser, B.
AU - Pillay, Y.
AU - Conradie, F.
AU - Gomez, G. B.
AU - Clayden, P.
AU - Matsolo, M.
AU - Amole, C.
AU - Rutter, L.
AU - Abdullah, F.
AU - Abrams, E. J.
AU - Casas, C. P.
AU - Barnhart, M.
AU - Pillay, A.
AU - Pozniak, A.
AU - Hill, A.
AU - Fairlie, L.
AU - Boffito, M.
AU - Moorhouse, M.
AU - Chersich, M.
AU - Serenata, C.
AU - Quevedo, J.
AU - Loots, G.
PY - 2016/12/21
Y1 - 2016/12/21
N2 - Antiretrovirals are a significant cost driver for HIV programmes. Current first-line regimens have performed well in real-life programmes, but have a low barrier to virological resistance and still carry toxicity that limits adherence. New drug developments may mean that we have access to safer, more robust and cheaper regimens, but only if the appropriate clinical trials are conducted. We briefly discuss these trials, and demonstrate the large cost savings to the South African HIV programme if these are successful.
AB - Antiretrovirals are a significant cost driver for HIV programmes. Current first-line regimens have performed well in real-life programmes, but have a low barrier to virological resistance and still carry toxicity that limits adherence. New drug developments may mean that we have access to safer, more robust and cheaper regimens, but only if the appropriate clinical trials are conducted. We briefly discuss these trials, and demonstrate the large cost savings to the South African HIV programme if these are successful.
UR - http://www.scopus.com/inward/record.url?scp=85047595955&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047595955&partnerID=8YFLogxK
U2 - 10.7196/SAMJ.2016.v107.i1.12058
DO - 10.7196/SAMJ.2016.v107.i1.12058
M3 - Article
C2 - 28112085
AN - SCOPUS:85047595955
SN - 0256-9574
VL - 107
SP - 28
EP - 30
JO - South African Medical Journal
JF - South African Medical Journal
IS - 1
ER -
